OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Morris on Treatment Advances Made in BRAF-Mutated mCRC

February 25th 2020

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALL

February 25th 2020

Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.

Dr. Comerci on the Utility of Primary Debulking Surgery in Ovarian Cancer

February 25th 2020

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

February 25th 2020

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC

February 25th 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Armstrong on AR-V7 as a Biomarker of Response to Taxane Chemotherapy in mCRPC

February 25th 2020

Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the potential of AR-V7 as a predictive biomarker of response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types

February 22nd 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Dr. Lazarides on CRM1 as a Potential Target in Osteosarcoma

February 22nd 2020

Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.

Dr. O'Reilly on Ongoing Trials With PARP Inhibitors in Pancreatic Cancer

February 22nd 2020

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses

Dr. Kopetz on the Rationale and Design of the BEACON CRC Study in mCRC

February 22nd 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.

Dr. Paulson on the Importance of Biomarker Testing in Oncology

February 22nd 2020

R. Steven Paulson, MD, discusses the importance of molecular testing in the era of precision medicine in oncology.

Dr. Hays on Immunotherapy Research in Gynecologic Cancer

February 22nd 2020

John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.

Dr. Coleman on the Safety Profile of Veliparib in Ovarian Cancer

February 22nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the safety profile of veliparib examined in the VELIA trial looking at patients with high-grade serous ovarian cancer.

Dr. Rossetti on Symptom Management for Patients With MPNs

February 22nd 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia

February 22nd 2020

Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.

Dr. Rampal on Investigational Agents in MPNs

February 22nd 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC

February 21st 2020

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Heyman on Frontline Treatment Options in Follicular Lymphoma

February 21st 2020

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.

Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

February 21st 2020

Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.